USA rapidly losing bioscience research market share to Asia

18 March 2015
china-big

The latest data from antibody search engine CiteAb suggests that the USA has continued to lose its share of the biosciences market at an alarming rate over the past year.

In February 2014 the search engine released data that suggested growth in China would result in the country soon claiming the lion’s share of global bioscience market, overtaking the USA within the next five to 10 years. Today, Andrew Chalmers, founder of CiteAb, says that the latest data suggests not only was this true, but that China could overtake the USA earlier than originally thought.

Dr Chalmers said: “Our data from CiteAb clearly shows that there has been a large spike in the number of Chinese research papers using antibodies over the last twelve months. Equally the number of US papers has dropped significantly. This data acts as a fantastic indicator of bioscience research activity.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical